The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models

Molecular and Cellular Biology

Volumn 33, Issue 19, 2013, Pages 3728-3734

  Krementsov, Dimitry N ^a   Thornton, Tina M ^a   Teuscher, Cory ^a   Rincon, Mercedes ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; HISTAMINE H1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VX 702;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CELL SPECIFICITY; CELL TYPE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INFLAMMATORY DISEASE; LIVER TOXICITY; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; STRESS; TH1 CELL; TH17 CELL; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION MEDIATORS; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 84886769705     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00688-13     Document Type: Short Survey

References (73)

1. Ebers GC. 2008. Environmental factors and multiple sclerosis. Lancet Neurol. 7:268-277.
2. Frohman EM, Racke MK, Raine CS. 2006. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354:942-955.
3. Greenstein JI. 2007. Current concepts of the cellular and molecular pathophysiology of multiple sclerosis. Dev. Neurobiol. 67:1248-1265.
4. Stromnes IM, Goverman JM. 2006. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 1:1810-1819.
5. Steinman L, Zamvil SS. 2006. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60:12-21.
6. Ramagopalan SV, Knight JC, Ebers GC. 2009. Multiple sclerosis and the major histocompatibility complex. Curr. Opin. Neurol. 22:219-225.
7. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'Alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214-219.
8. Blankenhorn EP, Butterfield R, Case LK, Wall EH, del Rio R, Diehl SA, Krementsov DN, Saligrama N, Teuscher C. 2011. Genetics of experimental allergic encephalomyelitis supports the role of T helper cells in multiple sclerosis pathogenesis. Ann. Neurol. 70:887-896.
9. Dong C. 2008. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8:337-348.
10. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744-748.
11. Segal BM. 2010. Th17 cells in autoimmune demyelinating disease. Semin. Immunopathol. 32:71-77.
12. Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A. 2011. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76:S20-S27.
13. Steinman L. 2005. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4:510-518.
14. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. 2009. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol. Med. 15:369-379.
15. Hui L, Bakiri L, Stepniak E, Wagner EF. 2007. p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 6:2429-2433.
16. Thornton TM, Rincon M. 2009. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int. J. Biol. Sci. 5:44-51.
17. Rincon M, Davis RJ. 2009. Regulation of the immune response by stressactivated protein kinases. Immunol. Rev. 228:212-224.
18. Ashwell JD. 2006. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 6:532-540.
19. Mittelstadt PR, Yamaguchi H, Appella E, Ashwell JD. 2009. T cell receptor-mediated activation of p38{alpha} by mono-phosphorylation of the activation loop results in altered substrate specificity. J. Biol. Chem. 284:15469-15474.
20. Liu W, Ouyang X, Yang J, Liu J, Li Q, Gu Y, Fukata M, Lin T, He JC, Abreu M, Unkeless JC, Mayer L, Xiong H. 2009. AP-1 activated by Toll-like receptors regulates expression of IL-23 p19. J. Biol. Chem. 284: 24006-24016.
21. Kikuchi K, Yanagawa Y, Iwabuchi K, Onoe K. 2003. Differential role of mitogen-activated protein kinases in CD40-mediated IL-12 production by immature and mature dendritic cells. Immunol. Lett. 89:149-154.
22. Aicher A, Shu GL, Magaletti D, Mulvania T, Pezzutto A, Craxton A, Clark EA. 1999. Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells. J. Immunol. 163:5786-5795.
23. Xie J, Qian J, Wang S, Freeman ME, III, Epstein J, Yi Q. 2003. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J. Immunol. 171:4792-4800.
24. Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, Bianchi R, Bozza S, Volpi C, Salomon BL, Fioretti MC, Romani L, Puccetti P. 2004. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 5:1134-1142.
25. Berenson LS, Yang J, Sleckman BP, Murphy TL, Murphy KM. 2006. Selective requirement of p38alpha MAPK in cytokine-dependent, but not antigen receptor-dependent, Th1 responses. J. Immunol. 176:4616-4621.
26. Noubade R, Milligan G, Zachary JF, Blankenhorn EP, del Rio R, Rincon M, Teuscher C. 2007. Histamine receptor H1 is required for TCRmediated p38 MAPK activation and optimal IFN-gamma production in mice. J. Clin. Invest. 117:3507-3518.
27. Rincon M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, Penix LA, Davis RJ, Flavell RA. 1998. Interferon-gamma expression by Th1 effector T cells mediated by the p38MAPkinase signaling pathway.EMBO J. 17:2817-2829.
28. Merritt C, Enslen H, Diehl N, Conze D, Davis RJ, Rincon M. 2000. Activation of p38 mitogen-activated protein kinase in vivo selectively induces apoptosis of CD8(+) but not CD4(+) T cells. Mol. Cell. Biol. 20: 936-946.
29. Schafer PH, Wadsworth SA, Wang L, Siekierka JJ. 1999. p38 alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. J. Immunol. 162:7110-7119.
30. Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD, Tuohy VK, Cua DJ, Li X. 2010. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32:54-66.
31. Li L, Kim J, Boussiotis VA. 2010. IL-1beta-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J. Immunol. 185:4148-4153.
32. Lu L, Wang J, Zhang F, Chai Y, Brand D, Wang X, Horwitz DA, Shi W, Zheng SG. 2010. Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells. J. Immunol. 184:4295-4306.
33. Commodaro AG, Bombardieri CR, Peron JP, Saito KC, Guedes PM, Hamassaki DE, Belfort RN, Rizzo LV, Belfort R, Jr, de Camargo MM. 2010. p38{alpha} MAP kinase controls IL-17 synthesis in Vogt-Koyanagi-Harada syndrome and experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 51:3567-3574.
34. Noubade R, Krementsov DN, Del Rio R, Thornton T, Nagaleekar V, Saligrama N, Spitzack A, Spach K, Sabio G, Davis RJ, Rincon M, Teuscher C. 2011. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 118:3290-3300.
35. Jirmanova L, Giardino Torchia ML, Sarma ND, Mittelstadt PR, Ashwell JD. 2011. Lack of the T-cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation. Blood 118:3280-3289.
36. Namiki K, Matsunaga H, Yoshioka K, Tanaka K, Murata K, Ishida J, Sakairi A, Kim J, Tokuhara N, Shibakawa N, Shimizu M, Wada Y, Tokunaga Y, Shigetomi M, Hagihara M, Kimura S, Sudo T, Fukamizu A, Kasuya Y. 2012. Mechanism for p38alpha-mediated experimental autoimmune encephalomyelitis. J. Biol. Chem. 287:24228-24238.
37. Han J, Brown T, Beutler B. 1990. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J. Exp. Med. 171:465-475.
38. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. 1999. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10:387-398.
39. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Muller M, Gaestel M, Resch K, Holtmann H. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18:4969-4980.
40. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G, Tsichlis PN. 2000. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ ERK-dependent pathway. Cell 103:1071-1083.
41. Hale KK, Trollinger D, Rihanek M, Manthey CL. 1999. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J. Immunol. 162: 4246-4252.
42. Risco A, del Fresno C, Mambol A, Alsina-Beauchamp D, MacKenzie KF, Yang HT, Barber DF, Morcelle C, Arthur JS, Ley SC, Ardavin C, Cuenda A. 2012. p38gamma and p38delta kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc. Natl. Acad. Sci. U. S. A. 109: 11200-11205.
43. Gonzalez-Teran B, Cortes JR, Manieri E, Matesanz N, Verdugo A, Rodriguez ME, Gonzalez-Rodriguez A, Valverde A, Martin P, Davis RJ, Sabio G. 2013. Eukaryotic elongation factor 2 controls TNF-alpha translation in LPS-induced hepatitis. J. Clin. Invest. 123:164-178.
44. Martino G, Furlan R, Brambilla E, Bergami A, Ruffini F, Gironi M, Poliani PL, Grimaldi LM, Comi G. 2000. Cytokines and immunity in multiple sclerosis: the dual signal hypothesis. J. Neuroimmunol. 109:3-9.
45. Owens T. 2002. Identification of new therapeutic targets for prevention of CNS inflammation. Expert Opin. Ther. Targets 6:203-215.
46. Bar-Or A, Oliveira EM, Anderson DE, Hafler DA. 1999. Molecular pathogenesis of multiple sclerosis. J. Neuroimmunol. 100:252-259.
47. Uccelli A, Pedemonte E, Narciso E, Mancardi G. 2003. Biological markers of the inflammatory phase of multiple sclerosis. Neurol. Sci. 24(Suppl 5):S271-S274.
48. Samoilova EB, Horton JL, Hilliard B, Liu TS, Chen Y. 1998. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161:6480-6486.
49. Schiffenbauer J, Streit WJ, Butfiloski E, LaBow M, Edwards C, III, Moldawer LL. 2000. The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin. Immunol. 95:117-123.
50. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-508.
51. Shin T, Ahn M, Jung K, Heo S, Kim D, Jee Y, Lim YK, Yeo EJ. 2003. Activation of mitogen-activated protein kinases in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 140:118-125.
52. Huang G, Wang Y, Vogel P, Kanneganti TD, Otsu K, Chi H. 2012. Signaling via the kinase p38alpha programs dendritic cells to drive TH17 differentiation and autoimmune inflammation. Nat. Immunol. 13:152-161.
53. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, Muller DN, Hafler DA. 2013. Sodium chloride drives autoimmune disease by the induction of pathogenic T17 cells. Nature 496:518-522.
54. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, Regev A, Kuchroo VK. 2013. Induction of pathogenic T17 cells by inducible saltsensing kinase SGK1. Nature 496:513-517.
55. Ji RR, Woolf CJ. 2001. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol. Dis. 8:1-10.
56. Ji RR, Gereau RW, IV, Malcangio M, Strichartz GR. 2009. MAP kinase and pain. Brain Res. Rev. 60:135-148.
57. Boyle DL, Jones TL, Hammaker D, Svensson CI, Rosengren S, Albani S, Sorkin L, Firestein GS. 2006. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Med. 3:e338. doi:10.1371/journal .pmed.0030338.
58. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M. 2009. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat. Rec. (Hoboken) 292:1902-1913.
59. Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W, Ransohoff RM, Bergmann C, Stohlman S, Tuohy VK, Li X. 2010. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 32:414-425.
60. Kehlen A, Thiele K, Riemann D, Langner J. 2002. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin. Exp. Immunol. 127:539-546.
61. Guo X, Harada C, Namekata K, Matsuzawa A, Camps M, Ji H, Swinnen D, Jorand-Lebrun C, Muzerelle M, Vitte PA, Ruckle T, Kimura A, Kohyama K, Matsumoto Y, Ichijo H, Harada T. 2010. Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol. Med. 2:504-515.
62. Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M, Han J. 2010. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology 138: 1255-1265.
63. Ritprajak P, Hayakawa M, Sano Y, Otsu K, Park JM. 2012. Cell typespecific targeting dissociates the therapeutic from the adverse effects of protein kinase inhibition in allergic skin disease. Proc. Natl. Acad. Sci. U. S. A. 109:9089-9094.
64. Guma M, Hammaker D, Topolewski K, Corr M, Boyle DL, Karin M, Firestein GS. 2012. Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum. 64:2887-2895.
65. Dambach DM. 2005. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr. Top. Med. Chem. 5:929-939.
66. Damjanov N, Kauffman RS, Spencer-Green GT. 2009. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebocontrolled clinical studies. Arthritis Rheum. 60:1232-1241.
67. Genovese MC. 2009. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 60:317-320.
68. Hammaker D, Firestein GS. 2010. "Go upstream, young man": lessons learned from the p38 saga. Ann. Rheum. Dis. 69(Suppl 1):i77-i82.
69. Bosch X, Saiz A, Ramos-Casals M. 2011. Monoclonal antibody therapyassociated neurological disorders. Nat. Rev. Neurol. 7:165-172.
70. Ghosh S. 2012. Biologic therapies: lessons from multiple sclerosis. Dig. Dis. 30:383-386.
71. Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C, Abecasis GR, Barrett JC, Behrens T, Cho J, De Jager PL, Elder JT, Graham RR, Gregersen P, Klareskog L, Siminovitch KA, van Heel DA, Wijmenga C, Worthington J, Todd JA, Hafler DA, Rich SS, Daly MJ. 2011. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 7:e1002254. doi:10.1371/journal.pgen.1002254.
72. Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB. 2006. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J. Immunol. 177:1913-1917.
73. Gorentla BK, Krishna S, Shin J, Inoue M, Shinohara ML, Grayson JM, Fukunaga R, Zhong XP. 2013. Mnk1 and 2 are dispensable for T cell development and activation but important for the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 190:1026-1037.